Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression

Multiple molecular agents have been developed for treating unresectable hepatocellular carcinoma. This study aimed to elucidate the clinical efficacy of sequential treatment with lenvatinib after regorafenib failure.

[1]  M. Kudo,et al.  What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure? , 2021, Liver Cancer.

[2]  M. Moriguchi,et al.  Transition of molecular target agent therapy in advanced hepatocellular carcinoma: A multicenter, retrospective study. , 2021 .

[3]  M. Kudo,et al.  Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade , 2020, Cancers.

[4]  J. H. Kim,et al.  Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea , 2020, Investigational New Drugs.

[5]  Myung Ah Lee,et al.  Regorafenib in patients with advanced Child‐Pugh B hepatocellular carcinoma: A multicentre retrospective study , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[6]  J. Marrero,et al.  Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference , 2020, Hepatology.

[7]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[8]  M. Kudo,et al.  Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma , 2020, Oncology.

[9]  N. Enomoto,et al.  Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice , 2019, Cancers.

[10]  Y. Hirooka,et al.  Clinical characteristics and outcomes of candidates for second‐line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

[11]  M. Kudo,et al.  Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma , 2019, Oncology.

[12]  N. Sugiura,et al.  Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan , 2019, Investigational New Drugs.

[13]  M. Kudo,et al.  Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis , 2019, Cancer medicine.

[14]  M. Kudo,et al.  Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein. , 2019, The Lancet. Oncology.

[15]  Y. Hiasa,et al.  Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma , 2018, Japanese journal of clinical oncology.

[16]  Y. Hiasa,et al.  Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[17]  J. Bruix,et al.  Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. , 2018, Journal of hepatology.

[18]  Gisela Schwab,et al.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.

[19]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[20]  M. Kudo,et al.  Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis. , 2018 .

[21]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[22]  M. Kudo,et al.  Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis , 2017, Digestive Diseases.

[23]  M. Kudo,et al.  Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function , 2017, Liver Cancer.

[24]  M. Kudo,et al.  Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update , 2017, Hepatology International.

[25]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[26]  H. Toyoda,et al.  Usefulness of albumin–bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma , 2016, Journal of gastroenterology and hepatology.

[27]  B. Sangro,et al.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Kawasaki,et al.  Evidence‐based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH‐HCC Guidelines) , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[29]  M. Kudo,et al.  Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update , 2014, Oncology.

[30]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[31]  U. Motosugi,et al.  Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. , 2011, Radiology.

[32]  Y. Hiasa,et al.  New contrast enhanced ultrasonography agent: Impact of Sonazoid on radiofrequency ablation , 2011, Journal of gastroenterology and hepatology.

[33]  C. Catalano,et al.  Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. , 2010, Radiology.

[34]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[35]  Haesook T. Kim.  Cumulative Incidence in Competing Risks Data and Competing Risks Regression Analysis , 2007, Clinical Cancer Research.

[36]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[37]  Chaofeng Liu,et al.  Adjusted Kaplan–Meier estimator and log‐rank test with inverse probability of treatment weighting for survival data , 2005, Statistics in medicine.

[38]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[39]  Y. Hiasa,et al.  Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid. , 2010, Oncology letters.

[40]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[41]  C. Gonçalves,et al.  [Hepatocellular carcinoma]. , 1988, Arquivos de gastroenterologia.